Table 3 Association of germline pathogenic mutations in guideline-recommended genes with lethal prostate cancer risk in the UK Biobank PCa patients with WES results

BRCA2

16 (4.1)

31 (0.56)

47 (0.80)

3.90 (2.34–6.51)

1.79 × 10^–7

PALB2

3 (0.77)

6 (0.11)

9 (0.15)

4.29 (1.36–13.50)

0.01

BRCA1

1 (0.26)

9 (0.18)

10 (0.17)

1.93 (0.27–13.93)

0.51

ATM

3 (0.77)

43 (0.78)

46 (0.78)

1.13 (0.36–3.53)

0.83

CHEK2

8 (2.0)

89 (1.62)

97 (1.64)

1.35 (0.67–2.73)

0.40

HOXB13

5 (1.3)

63 (1.14)

68 (1.15)

1.16 (0.48–2.81)

0.74

MSH2

0

0

0

N/A

N/A

MSH6

2 (0.51)

22 (0.40)

24 (0.41)

1.50 (0.37–6.05)

0.57

MLH1

1 (0.26)

0

1 (0.02)

N/A

N/A

PMS2

1 (0.26)

11 (0.20)

12 (0.20)

1.08 (0.15–7.63)

0.95

MMR (4 genes)

4 (1.0)

33 (0.60)

37 (0.63)

1.65 (0.61–4.41)

0.33

DDR (9 genes)

35 (8.93)

208 (3.78)

243 (4.12)

2.13 (1.48–3.06)

5.12 × 10^–5

BRCA2/PALB2

19 (4.8)

37 (0.67)

56 (0.95)

4.00 (2.50–6.41)

7.47 × 10^–9